Boehringer Bemoans Medicare Drug Price Talks As 'A Sham'

By Theresa Schliep · September 28, 2023, 7:38 PM EDT

Boehringer Ingelheim Pharmaceuticals Inc. slammed the new Medicare drug price negotiation program in a Connecticut federal court filing as a "sham from beginning to end," even as it indicated Thursday that...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Memorandum

Case Information

Case Title

Boehringer Ingelheim Pharmaceuticals, Inc. v. United States Department of Health and Human Services et al

Case Number

3:23-cv-01103

Court

Connecticut

Nature of Suit

Other Statutes: Administrative Procedures Act/Review or Appeal of Agency Decision

Date Filed

August 18, 2023

Recent Articles By Theresa

December 13, 2024
What's Left In $400M Skinny Label Row? A Lot, Court Says
November 27, 2024
Deloitte Posed As Consultant To Steal Vax Software, Suit Says
November 25, 2024
Hormone Therapy Co. Jilted Actress Over Image Use, Suit Says
November 25, 2024
Ex-Epstein Becker Healthcare Ace Joins Polsinelli Team
November 19, 2024
Nonpracticing Doc Can't Testify In Med Mal Case, Court Says
November 15, 2024
Despite Vaccine Spotlight, RFK Jr. A Health Policy 'Unknown'
November 14, 2024
Trump Picks RFK Jr. To Lead Health & Human Services
November 12, 2024
Why The CDC May Look Very Different In Trump's 2nd Term
November 05, 2024
Abortion Ballot Tracker: 7 States Add Protections As Fla. Effort Fails
October 29, 2024
Fla. Health Agency's All-Out Battle Against Abortion Measure